Skip to main content
logo
Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
14.73
+0.17 (1.17%)
Aug 26, 2026, 4:00 PM EDT - Market closed

Corvus Pharmaceuticals Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
1,2395753448640112
Market Cap Growth
199.59%67.27%298.31%118.11%-64.73%12.29%
Enterprise Value
1,02551030256-740
Last Close Price
14.737.705.351.760.852.41

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
5.509.4010.562.230.711.16
P/TBV Ratio
5.509.4010.562.230.711.16

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.000.020.030.040.050.04
Net Debt / Equity Ratio
-0.95-0.91-1.56-0.67-0.71-0.68
Net Debt / EBITDA Ratio
3.771.301.851.111.261.74
Net Debt / FCF Ratio
4.741.692.001.081.461.79
Quick Ratio
15.886.091.473.963.997.22
Current Ratio
16.166.211.544.074.067.36
Return on Equity (ROE)
-35.43%-32.60%-174.85%-57.02%-53.90%-51.08%
Return on Assets (ROA)
-21.66%-38.36%-30.09%-25.63%-22.50%-24.61%
Return on Capital Employed (ROCE)
-25.20%-69.60%-82.20%-60.30%-55.60%-38.50%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Aug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-4.37%-2.66%-18.12%-31.32%-104.39%-38.55%
FCF Yield
-3.65%-5.73%-7.40%-27.77%-68.97%-32.73%
Buyback Yield / Dilution
-22.16%-30.76%-26.99%-3.16%-11.23%-41.98%
SEC Filings: 10-K · 10-Q